All In Biotech

NDA 211226 · Acrotech Biopharma

Khapzory

Levoleucovorin · Intravenous

Orphan

Last checked: Nov 20, 2026Latest source record: Mar 3, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 19, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,253

339 Phase 3, 166 recruiting

FAERS reports

757

737 serious, 44 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 17, 2026.

KHAPZORY is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination adult and pediatric patients. The treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use KHAPZORY is not indicated for pernicious anemia and megaloblastic anemia secondary to lack the of vitamin B 12 because of the risk of progression of neurologic manifestations despite hematologic remission. KHAPZORY is a folate analog indicated for: Rescue after high-dose methotrexate therapy in adults and pediatric patients with osteosarcoma. ( 1 ) Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. ( 1 ) Treatment of adults with metastatic colorectal cancer in combination with fluorouracil. ( 1 ) Limitations of Use KHAPZORY is not indicated for pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 because of the risk of progression of neurologic manifestations despite hematologic remission.( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 19, 2018 Original approval · Type 2 - New Active Ingredient OrphanLabelLetterReview
2 products under this application
  • KHAPZORY · LEVOLEUCOVORIN 300MG/VIAL · POWDER, INTRAVENOUS · Discontinued
  • KHAPZORY · LEVOLEUCOVORIN 175MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Levoleucovorin" as an intervention, any sponsor and status, largest first.

All 1,253 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia125
  • thrombocytopenia78
  • asthenia76
  • off label use75
  • diarrhoea64
  • nausea60
  • azotaemia59
  • anaemia37
  • vomiting35
  • pyrexia30
  • febrile neutropenia28
  • neuropathy peripheral23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20092
20128
20144
20153
20162
20173
201871
201955
202019
202129
202255
2023161
2024140
2025139
202666

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Khapzory (Levoleucovorin) · HCPCS J0642

2024 spending

$1.0M

Beneficiaries

110

786 claims

Per beneficiary

$9,261

2024 ASP limit $1.58 per unit

View as table
YearSpending
2020$2,125,122
2021$1,827,629
2022$1,136,989
2023$1,105,731
2024$1,018,757

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Acrotech Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.